Pune: Towards the drive vaccination of the door to the door proposed by the center, members of the national task force have ruled out vaccine shortages to drive with almost 30 crore vaccines to be purchased from manufacturers every month which includes almost 25 doses of cr.
from covishield and 5 covaxin doses.
However, the last miles connectivity will continue to be a difficult task to ensure the maximum coverage of the first and second dose, stated as an official.
“There is absolutely no shortage of vaccines for the travel vaccination trip to the door proposed as the production according to the target.
The availability of vaccines is no longer a problem since September.
The problem is to ensure the maximum coverage at the earliest,” said National Task Member Stated Dr.
NK Arora .
While the covishield dose almost consists of 90% of shares, Bharat Biotech also increases the production of covaxin and the country will see ZY-COV-D also joined this month’s stockpile with about 1 expected crore dose.
January is expected to see three more vaccines from biological E, Novovax and Genova biopharma added.
Dr.
Arora explained that the scope of “last miles” will definitely be a difficult task because it must ensure the scope of the beneficiaries of its difficult media, daily wage workers who cannot reach their vaccination centers because they lose wages or those whether vaccine doubt and The door vaccination to the door is to maintain the momentum of vaccination as it starts in January.
“The door to the vaccination door to complete the last mile from covers 20% for the first dose was taken from a polio drive.
We started it as a trip throughout the month and will be followed up again if needed,” he told Toi.
But the strategy will be the same to ensure that nothing is left, he shares.
At present there are 134 million beneficiaries, which have not taken a second shot even after the specified interval, according to government data.
A total of 77% of the eligible population in India has been vaccinated against Covid-19 with the first dose, and 32% of the population has received the dose.